Neocartilage compositions and methods for modifying proteoglycan content
View Patent ↗The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.
1. A cartilage replacement composition comprising:
neocartilage maintained at a temperature below physiologic temperature and comprising a reduced proteoglycan content relative to the proteoglycan content of the neocartilage at a physiological temperature, wherein the neocartilage is maintained at the temperature below the physiologic temperature for a period of time sufficient for the proteoglycan content of the neocartilage to decrease relative to the proteoglycan content of the neocartilage at a physiological temperature, wherein the storage period is at least about 1 week, wherein the temperature below physiologic temperature is about 30° C. or lower, and wherein the neocartilage at the temperature of about 30° C. or lower is capable of increasing the proteoglycan content when returned to a physiological temperature.
2. A cartilage replacement composition of claim 1 wherein the neocartilage is prepared ex vivo from isolated chondrocytes.
3. The cartilage replacement composition of claim 1 , wherein the proteoglycan content comprises aggrecan content.
4. The cartilage replacement composition of claim 1 , wherein the proteoglycan content comprises sulfated glycosaminoglycan (S-GAG) content.
5. The cartilage replacement composition of claim 1 , wherein an initial proteoglycan content of the neocartilage at a physiological temperature before being maintained at about 30° C. or lower, comprises an initial S-GAG content of at least about 400 μg/cm2 or at least about 800 μg/cm2.
6. The cartilage replacement composition of claim 1 , wherein an initial proteoglycan content of the neocartilage at a physiological temperature before being maintained at about 30° C. or lower, comprises an initial S-GAG content of from about 800 μg/cm2 to about 2500 μg/cm2.
7. The cartilage replacement composition of claim 4 , wherein the composition is substantially free of type I, III and X collagen.
8. The cartilage replacement composition of claim 4 , wherein the initial proteoglycan content of the composition indicates cartilage enriched in high molecular weight aggrecan.
9. The cartilage replacement composition of claim 8 , wherein the high molecular weight aggrecan comprises at least about 80% of the initial proteoglycan content of the cartilage.
10. The cartilage replacement composition of claim 8 , wherein the high molecular weight aggrecan comprises at least about 90% of the initial proteoglycan content of the cartilage.
11. The cartilage replacement composition of claim 1 , wherein the composition comprises articular chondrocytes obtained from a human or animal donor.
12. The cartilage replacement composition of claim 7 , wherein the composition comprises articular chondrocytes obtained from a cadaver.
13. The cartilage replacement composition of claim 8 , wherein the composition comprises an implant.
14. The cartilage replacement composition of claim 1 , wherein the composition is maintained at a temperature of about 20-30° C. and enclosed in a sealed container.
15. The cartilage replacement composition of claim 1 , wherein the storage period is, at least about 2 weeks, at least about 30 days, at least about 50 days, or at least about 60 days.
16. The cartilage replacement composition of claim 1 , wherein the composition is maintained in a serum-free medium.